Serum HE4 and CA125 have shown improved effectiveness over existing methods for riskstratification of endometrioid carcinomas, highlighting the need for further investigation [20].Serum HE4, more than CA125, shows promise as a diagnostic biomarker for endometrial cancer and is associated with markers of diseaseseverity that could assist in pre-operative staging. This evidence concerns the gene WFDC2 and endometrioid adenocarcinoma.